A brief description of the medication guide for Ripotinib (Augtyro)

Repotrectinib, the English name isRepotrectinib, the trade name is Augtyro, and the Chinese trade name is Aokele, it is a new type of tyrosine kinase inhibitor (TKI). This drug specifically targets ROS1 and NTRK gene fusion. It was developed by Bristol-Myers Squibb and launched in the Chinese market. Ripotinib effectively inhibits the activity of ROS1 and NTRK oncogenic factors, thereby blocking the proliferation and spread of tumor cells, providing a new treatment method for patients with ROS1-positive non-small cell lung cancer (NSCLC) and NTRK gene fusion solid tumors. It is worth mentioning that Ripotinib has the ability to break through multiple drug resistance problems and shows strong therapeutic potential against a variety of tumor cells carrying ROS1 or NTRK gene fusions.

Before taking repotinib, patients should fully understand its administration method, dosage, possible adverse reactions and precautions. The recommended dosage for adult patients is 160 mg taken orally once daily (i.e. four 40 mg capsules). After continuous use for 14 days, the frequency of medication is increased to twice a day, maintaining a dose of 160 mg each time, until the condition changes or intolerable side effects occur. Ripotinib can be taken with or without meals, but it is recommended to take it at a fixed time every day to ensure that the concentration of the drug in the blood remains stable.

During treatment with repotinib, patients may experience a series of adverse reactions, including but not limited to dizziness, abnormal taste, constipation, nausea, shortness of breath, fatigue, and cognitive decline. Most of these adverse reactions are mild to moderate and can be tolerated by most patients. However, some patients may experience more serious adverse reactions, such as effects on the central nervous system (such as hallucinations, dizziness, etc.), lung problems (such as pneumonia, etc.), abnormal liver function, muscle problems, and hyperuricemia. Once patients develop these symptoms, they should immediately report to their doctor so that the treatment plan can be adjusted in a timely manner or corresponding countermeasures can be taken.

Caution is required when using reputinib in certain populations, such as pregnant women, lactating women, men and women of childbearing potential, and patients with impaired hepatic and renal function. Pregnant women should avoid using this drug, and nursing women should suspend breastfeeding during treatment and for some time after stopping the drug. For men and women of childbearing potential, it is recommended that effective contraceptive measures be used during treatment and for a period of time after discontinuation of Ripotinib because of its possible effects on the health of future fetuses.

In general, as a new type of anti-cancer drug, repotinib provides a new treatment option for patients with ROS1-positive non-small cell lung cancer and NTRK gene fusion solid tumors. However, during use, patients should strictly abide by the doctor's medication instructions, understand and identify possible adverse reactions, so that the treatment plan can be adjusted in a timely manner or corresponding countermeasures can be taken. Currently, there are both the original version of Ripotinib and the more affordable Laotian generic version for patients to choose from.

References:

https://www.drugs.com/search.php?searchterm=Augtyro&sources%5B%5D=professional